Vyne Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of cancer. The company's lead product candidate, VY-1001, is a first-in-class, small molecule inhibitor of the protein kinase AKT1 that is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Vyne Therapeutics is also developing a pipeline of other potential therapies for the treatment of cancer.